FibroBiologics (FBLG) Total Current Liabilities (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Total Current Liabilities of $2.2 million for Q2 2026, down 79.82% year-over-year from $11.0 million in Q2 2025, and up 21.0% on a QoQ basis from $1.8 million in Q1 2026.
FibroBiologics (FBLG) Total Current Liabilities (2022 - 2026) Analysis & Trends
FibroBiologics has reported Total Current Liabilities for 5 years, with the latest figure at $2.2 million in Q2 2026.
- Total Current Liabilities for Q2 2026 came in at $2.2 million, down 79.82% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.2 million (down 79.82% YoY), and the FY2025 annual result was $1.8 million, down 86.18% from the prior year.
- Total Current Liabilities grew to $2.2 million in Q2 2026, from $1.8 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $14.0 million in Q1 2024 and troughed at $1.8 million in Q4 2025.
- A 5-year average of $7.6 million and a median of $7.6 million in 2022 frame the typical range for Total Current Liabilities.
- The widest annual swing landed in 2024, when Total Current Liabilities soared 38.58%; it then sank 86.18% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $7.1 million in 2022, then advanced by 29.83% to $9.2 million in 2023, then soared by 38.58% to $12.7 million in 2024, then sank by 86.18% to $1.8 million in 2025, then rose by 25.81% to $2.2 million in 2026.
- Per Business Quant data, the three most recent Total Current Liabilities figures were $2.2 million in Q2 2026, $1.8 million in Q1 2026, and $1.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | FibroBiologics | 9.06 Mn | 9.06 Mn | - | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | 1.83 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | 6.72 Mn |
| Jun 30, 2025 | 10.96 Mn |
| Mar 31, 2025 | 8.21 Mn |
| Dec 31, 2024 | 12.73 Mn |
| Sep 30, 2024 | 6.68 Mn |
| Jun 30, 2024 | 10.13 Mn |
| Mar 31, 2024 | 13.99 Mn |
| Dec 31, 2023 | 9.18 Mn |
| Dec 31, 2022 | 7.07 Mn |